U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H7N2O5.Na
Molecular Weight 330.2269
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRENOXINE SODIUM

SMILES

[Na+].OC1=CC(=NC2=C1C3=NC4=CC=CC=C4OC3=CC2=O)C([O-])=O

InChI

InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M
InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1

HIDE SMILES / InChI

Description

Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CATALIN

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the solution, 3-5 times a day
Route of Administration: Other
In Vitro Use Guide
Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.